Tactics of managing a patient with fatty liver disease coursing in the background of a polyorgan digestive tract: clinical observation

Preparations of glycyrrhizic acid (GA) and ursodeoxycholic acid (UDCA) are effective in the treatment of various forms of non-alcoholic fatty liver disease (NAFLD) and gastroesophageal reflux disease (GERD) occurring against the background of duodeno-gastroesophageal reflux. However, their effectiveness in the treatment of hologenic diarrhea and reflux gastritis has not been sufficiently studied. Currently, there are no clinical guidelines for the diagnosis and treatment of patients with hologenic diarrhea and reflux gastritis, including those with obesity and NAFLD. It is assumed that the combined administration of GA and UDCA can be accompanied by a mutual potentiation of the effect of the drugs. The article presents a clinical case of a patient with NAFLD, obesity, dyslipidemia, GERD, refractory to treatment with proton pump inhibitors, associated with duodenogastroesophageal reflux, reflux gastritis and hologenic diarrhea. It was shown that GERD, reflux gastritis, and hologenic diarrhea developed in the long-term period after cholecystectomy. At the same time, the appointment of a complex preparation containing GA (35 mg) and UDCA (250 mg) made it possible to stop the manifestations of a typical reflux syndrome in patients with a form of GERD refractory to proton pump inhibitors, reflux gastritis, and diarrheal syndrome associated with an excess of bile acids, improve lipid profile parameters. It has been shown that the administration of GA (35 mg) and UDCA (250 mg) can improve the parameters of the intestinal microbiome and lipid metabolism, which can be used in the treatment of patients with atherogenic dyslipidemia. At the same time, patients with comorbid pathology, including NAFLD, GERD, reflux esophagitis, hologenic diarrhea, and dyslipidemia require long-term maintenance therapy with GA (35 mg) and UDCA (250 mg).

1. Dedov I.I., Shestakova M.V., Galstyan G.R. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes Mellitus. 2016;(2):104–112. (In Russ.) https://doi.org/10.14341/DM2004116-17.

2. Fabbrini E., Sullivan S., Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51(2):679–689. https://doi.org/10.1002/hep.23280.

3. Sarwar R., Pierce N., Koppe S. Obesity and nonalcoholic fatty liver disease: current perspectives. Diabetes Metab Syndr Obes. 2018;11:533–542. https://doi.org/10.2147/DMSO.S146339.

4. Eusebi L.H., Ratnakumaran R., Yuan Y., Solaymani Dodaran M., Bazzoli F., Ford A.C. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67(3):430–440. https://doi.org/10.1136/gutjnl-2016-313589.

5. Liu J., Lin H., Zhang C., Wang L., Wu S., Zhang D. et al. Non-alcoholic fatty liver disease associated with gallstones in females rather than males: a longitudinal cohort study in Chinese urban population. BMC Gastroenterol. 2014;14:213. https://doi.org/10.1186/s12876-014-0213-y.

6. Borly L., Anderson I.B., Bardram L., Christensen E., Sehested A., Kehlet H. et al. Preoperative prediction model of outcome after cholecystectomy for symptomatic gallstones. Scand J Gastroenterol. 1999;34(11):1144–1152. https://doi.org/10.1080/003655299750024968.

7. Livzan M.A., Lapteva I.V., Korolevets T.S., Kiselev I.E. Specific features of gastroesophageal reflux disease associated with obesity and over-weight. Terapevticheskii Arkhiv. 2016;(2):21–27. (In Russ.) Available at: https://ter-arkhiv.ru/0040-3660/article/view/31908/pdf.

8. Fisher M., Spilias D.C., Tong L.K. Diarrhoea after laparoscopic cholecystectomy: incidence and main determinants. ANZ J Surg. 2008;78(6):482–486. https://doi.org/10.1111/j.1445-2197.2008.04539.x.

9. Bystrovskaya E.V., Ilchenko A.A., Silvestrova S.Yu. Biochemical composition of operating bile in various types of cholecystolithiasis. Experimental and Clinical Gastroenterology. 2010;(6):3–6. (In Russ.) Available at: https://med-click.ru/uploads/files/docs/osobennosti-biohimicheskogo-sostava-operatsionnoy-zhelchi-pri-razlichnyh-vidah-holetsistolitiaza.pdf.

10. Krums L.M., Parfenov A.I., Gubina A.V., Silvestrova S.Yu., Smirnova A.V. Cholagenic diarrhea is a type of postcholescystectomy syndrome. Terapevticheskii Arkhiv. 2013;(2):32–35. (In Russ.) Available at: https://ter-arkhiv.ru/0040-3660/article/view/31199.

11. Litvinova N.V., Osipenko M.F., Voloshina N.B., Kholin S.I. Postcholecystectomy syndrome: heartburn syndrome in patients 6 months after cholecystectomy for cholelithiasis. Experimental and Clinical Gastroenterology. 2013;(10):51–52. (In Russ.)

12. Sureka B., Mukund A. Review of imaging in post-laparoscopy cholecystectomy complications. Indian J Radiol Imaging. 2017;27(4):470–481. https://doi.org/10.4103/ijri.IJRI_489_16.

13. Shah Gilani S.N., Bass G.A., Kharytaniuk N., Downes M.R., Caffrey E.F., Tobbia I., Walsh T.N. Gastroesophageal Mucosal Injury after Cholecystectomy: An Indication for Surveillance? J Am Coll Surg. 2017;224(3):319–326. https://doi.org/10.1016/j.jamcollsurg.2016.12.003.

14. Mercan E., Duman U., Tihan D., Dilektasli E., Senol K. Cholecystectomy and duodenogastric reflux: interacting effects over the gastric mucosa. Springer Plus. 2016;5(1):1970. https://doi.org/10.1186/s40064-016-3641-z.

15. Yue W., Sun X., Du T. Cholecystectomy versus central obesity or insulin resistance in relation to the risk of nonalcoholic fatty liver disease: the third US National Health and Nutrition Examination Survey. BMC Endocr Disord. 2019;19(1):95. https://doi.org/10.1186/s12902-019-0423-y.

16. Marschall H.U., Wagner M., Zollner G., Fickert P., Lackner C., Thorell A., Trauner M. Ursodeoxycholic acid for treatment of fatty liver disease and dyslipidemia in morbidly obese patients. Dig Dis. 2011;29(1):117–118. https://doi.org/10.1159/000324146.

17. Zhao Z.F., Gao H.L., Yao P. Ursodeoxycholic acid for treatment of bile reflux gastritis: a systematic review. World Chinese Journal of Digestology. 2013;21(26):2708–2716. https://doi.org/10.11569/wcjd.v21.i26.2708.

18. Lishchuk N.B., Simanenkov V.I., Tikhonov S.V. Differentiation therapy for non-acidic gastroesophageal reflux disease. Terapevticheskii Arkhiv. 2017;(4):57–63. (In Russ.) https://doi.org/10.17116/terarkh201789457-63.

19. Zhou Y., Doyen R., Lichtenberger L.M. The role of membrane cholesterol in determining bile acid cytotoxicity and cytoprotection of ursodeoxycholic acid. Biochim Biophys Acta. 2009;1788(2):507–513. https://doi.org/10.1016/j.bbamem.2008.12.008.

20. Martínez-Moya P., Romero-Calvo I., Requena P., Hernández-Chirlaque C., Aranda C.J., González R. et al. Dose-dependent antiinflammatory effect of ursodeoxycholic acid in experimental colitis. Int Immunopharmacol. 2013;15(2):372–380. https://doi.org/10.1016/j.intimp.2012.11.017.

21. Ward J.B.J., Lajczak N.K., Kelly O.B., O’Dwyer A.M., Giddam A.K., Gabhann J.N. et al. Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon. Am J Physiol Gastrointest Liver Physiol. 2017;312(6):G550–G558. https://doi.org/10.1152/ajpgi.00256.2016.

22. Pearson T., Caporaso J.G., Yellowhair M., Bokulich N.A., Padi M., Roe D.J. et al. Effects of ursodeoxycholic acid on the gut microbiome and colorectal adenoma development. Cancer Med. 2019;8(2):617–628. https://doi.org/10.1002/cam4.1965.

23. Okovity S.V., Raikhelson K.L., Volnukhin A.V., Kudlai D.A. Hepatoprotective properties of glycyrrhizic acid. Experimental and Clinical Gastroenterology. 2020;(12):96–108. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-184-12-96-108.

24. Yan T., Wang W., Cao L., Wang Q., Takahashi S., Yagai T. et al. Glycyrrhizin Alleviates Nonalcoholic Steatohepatitis via Modulating Bile Acids and Meta-Inflammation. Drug Мetab Dispos. 2018;46(9):1310–1319. https://doi.org/10.1124/dmd.118.082008.

25. Raveendra K.R., Jayachandra, Srinivasa V., Sushma K.R., Allan J.J., Goudar K.S. et al. An Extract of Glycyrrhiza glabra (GutGard) Alleviates Symptoms of Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Study. Evid Based Complement Alternat Med. 2012;2012:216970. https://doi.org/10.1155/2012/216970.

26. Taylor T.V. Gastro-oesophageal reflux disease. Br J Surg. 1995;82(5):579–581. https://doi.org/10.1002/bjs.1800820503.

27. van der Heijden H.S., Tabbers M.M. GER and Complementary Medicine. In: Vandenplas Y. (ed.) Gastroesophageal Reflux in Children. Springer; 2017, pp. 293–301.https://doi.org/10.1007/978-3-319-60678-1_21.

28. Wang C., Chen H., Xiong Y., Zhang J., Yang J., Liu X. et al. Modulation of intestinal microbiota by glycyrrhizic acid prevents high-fat diet-enhanced pre-metastatic niche formation and metastasis. Mucosal Immunol. 2019;12(4):945–957. https://doi.org/10.1038/s41385-019-0144-6.

29. Bordin D.S., Valitova E.R.; Lazebnik L.B. (ed.) Methodology and clinical signif­ icance of esophageal manometry. Moscow: Medpraktika-M; 2009. 24 p. (In Russ.) Available at: https://mosgorzdrav.ru/ru-RU/science/default/download/229.html?ysclid=l168izzh8j.

30. Kolesnikova I.Yu. Quantitative-Qualitative assessment of Duo-Denogastric Reglux in 24-H PH-Metry. Terapevticheskii Arkhiv. 2006;(2):32–35. (In Russ.)

31. Osipov G.A., Parfyonov A.I., Verkhontseva N.V., Ruchkina I.N., Kurchavov V.A., Boiko N.B., Rogatina Е.L. Clinical value of studies of the bowel mucous coat microorganisms by cultural-biochemical and chromato-mass-spectrometric methods. Experimental and Clinical Gastroenterology. 2003;(4):59–67. (In Russ.) Available at: http://www.rusmedserv.com/microbdiag/klgastart.htm.

32. Ovadia C., Perdones-Montero A., Fan H.M., Mullish B.H., McDonald J.K., Papacleovoulou G. et al. Ursodeoxycholic acid enriches intestinal bile salt hydrolase-expressing Bacteroidetes in cholestatic pregnancy. Sci Rep. 2020;10(1):3895. https://doi.org/10.1038/s41598-020-60821-w.